ABOUT US
Well-known founders, convinced investors and research-strong employees: Together we are advanceCOR GmbH.
advanceCOR exists since June 2012 and emerged from Corimmun GmbH, which was sold to Janssen Cilag GmbH/Johnson & Johnson. The founding team includes well-known scientists, who still actively shape the course of advanceCOR today.
2012
The Beginnings
In June 2012 the predecessor company of advanceCOR, Corimmun GmbH, was sold. Janssen Cilag GmbH, a subsidiary of Johnson & Johnson, paid a purchase price of USD 100 million for this. All projects not related to the main project (COR-1) were transferred to the newly founded advanceCOR GmbH.
2013
Revacept Phase II
In March 2013, the first Revacept Phase II study started with 150 patients who had recently suffered a stroke or transient ischaemic attack (TIA) (EudraCT No 2011-001006-10). It was a double-blind, randomised, placebo-controlled trial.
2017
Second Phase II
In November 2017, a second Phase II study with Revacept in 332 patients suffering from stable coronary heart disease (CHD) started (EudraCT No 2015-000686-32). This so called ISAR-plaster trial was a double-blind, randomised, placebo-controlled trial, as well.
2019
1. Revacept Phase II Completed
In September 2019, the last patient with a narrowing of the carotid artery (carotid stenosis) and the increased risk of stroke completed the first Revacept Phase II study, which started in 2013. Magnetic resonance imaging (DW-MRI) showed that the Revacept treated group had fewer strokes than the control group. Revacept did not increase the risk of severe bleeding – an important difference to current drugs. Conclusion: the combined clinical endpoint (serious ischaemic events combined with bleeding) occurred less frequently.
2020
2. Revacept Phase II Completed
In March 2020, we completed our second Revacept Phase II study, which started in 2017 in patients with stable coronary heart disease (CHD). The results showed increased platelet inhibition without bleeding complications. As standard of care treatment, all patients had additionally received platelet-inhibiting drugs at maximum dosage. Thus, Revacept proved again the excellent safety also in combination with dual antiplatelet therapy.
2021
Post Hoc Analysis
In post hoc analysis of our Revacept Phase II studies, patients with more severe disease have been identified to benefit the most from our new drug candidate.
Further, the predictive capacity of soluble GPVI for bleeding risks at percutaneous coronary intervention (PCI) was evaluated in a biomarker sub-study of the ISAR-plaster trial, our second phase II study.
2023
Repositioning of Revacept
With a team from outstanding experts, peripheral arterial disease (PAD) was identified as large unmet medical need. With its plaque-specific thrombus inhibition, Revacept addresses the key step for PAD. Advancecor is preparing a phase II efficacy study in patients with PAD to fill this treatment gap.
Our Team
We are a small company with about twenty competent, committed employees. Our scientists come from the fields of medicine, pharmacy, biology and chemistry and have a lot of experience in the biotech industry. We are convinced of our pipeline and we take any effort to bring it from research to the patient.
Prof. Dr. Götz Münch
CEO Internist and CardiologistGötz Münch is co-founder and managing director of advanceCOR GmbH, Martinsried, a Biotech company dedicated to the development of cardiovascular drugs. He was co-founder and managing director of Corimmun GmbH, which was successfully sold to Johnson & Johnson in 2012. Previously, he founded and managed ProCorde GmbH, where he was responsible for the site in Martinsried after successful merger with the English Biotech company TRIGEN (London, UK) from 2005.
After completion of his MD thesis at the Pharmacology Department of the University Freiburg at Prof. Dr. K. Starke and at the University College London at Prof. Dr. G. Burnstock in 1992, he made his PhD (Habilitation) in 2004 in Pharmacology at the University Würzburg. Since 2012 he is appointed assistant professor at the University of Würzburg.
He is consultant (Facharzt) for Internal Medicine and Cardiology and is lecturer in Biomedicine at the Julius-Maximilians-Universität Würzburg and teaches in the field of physiology/pathophysiology since 2001.
Götz is currently responsible for investor relations and the general funding and strategy of advanceCOR as Chief Executive officer. He is mainly responsible for the clinical development of the projects at advanceCOR. He planned and managed one phase I and two phase II multi-national studies as sponsor of the trial and in cooperation with an investigator-initiated study. He took the role of the Clinical Research Physician responsible for the design, preparation of the study including the approval with ethic committees and drug authorities and pharmacovigilance during the course of the study.
Prof. Dr. Götz Münch
CEOInternist and Cardiologist
Prof. Dr. Meinrad Gawaz
Medical Director University Hospital TübingenAfter completing his medical studies at the Technischen Universität München (TUM, Germany), Meinrad Paul Gawaz has entered his clinical and academic career in the field of cardiology and cardiovascular science. He has become an international renowned clinician and vascular biologist.
Since October 2004, he has been appointed as Medical Director of the department of Internal Medicine III, cardiology and angiology at the University Hospital of Tübingen and as full professor (C4) of internal medicine/cardiology/angiology at the Eberhard Karls Universität of Tübingen.
The focus of his scientific work is on mechanisms of inflammation and thrombosis and antithrombotic therapy in cardiovascular disease. He is one of the leading experts in the field of platelet research. His clinical work concentrates on interventional cardiology and structural heart disease.
In 2004 Meinrad Gawaz was awarded the Alexander Schmidt Price (Thrombosis and Hemostasis Research Society) and in 2022 the Paul-Morawitz-Price (German Society for Cardiology). The price is awarded to physicians from German-speaking countries for outstanding research achievements in the field of cardiology. In 2023 he received the Rudolf Schönheimer Medal (German Atherosclerosis Society) for his eminent contribution to the atherosclerosis research.
Prof. Dr. Meinrad Gawaz
Medical DirectorUniversity Hospital Tübingen
Prof. Dr. Martin Lohse
Chairman of ISAR Bioscience GmbH PharmacologistMartin Lohse leitet ISAR Bioscience. Er studierte Medizin und Philosophie an den Universitäten Göttingen, London und Paris und forschte an den Universitäten Bonn, Heidelberg, Durham (NC, USA) sowie am Genzentrum München. Seit 1993 ist er Professor für Pharmakologie an der Universität Würzburg, von 2016 bis 2019 leitete er das Max-Delbrück-Centrum in Berlin. Er ist außerdem Honorarprofessor für Biochemie an der FU Berlin.
Martin Lohse hat zahlreiche nationale und internationale Auszeichnungen erhalten, darunter den Leibniz-Preis, die höchste Auszeichnung in der deutschen Wissenschaft. Er ist Mitglied vieler Wissenschaftsakademien und war von 2009 bis 2019 Vizepräsident der Nationalen Akademie der Wissenschaften Leopoldina. Seit 2019 ist er Präsident der Gesellschaft Deutscher Naturforscher und Ärzte (GDNÄ).
Martin Lohse gehört zu den Gründern der Biotechnologiefirmen ProCorde, CorImmun und AdvanceCOR. Seine wissenschaftlichen Interessen gelten der Arzneimittelforschung und besonders der Erforschung von Rezeptoren als Angriffspunkte für neuartige Arzneimittel gegen Erkrankungen des Herz-Kreislauf-Systems und des Nervensystems.
Prof. Dr. Martin Lohse
Chairman of ISAR Bioscience GmbHPharmacologist
Claus Schalper
CBOWith his broad expertise as biotech entrepreneur, Claus serves as CBO of AdvanceCor. Claus is a serial entrepreneur in the Life Sciences with 20 years’ experience in the Industry. In 2001, he cofounded Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and executed the listing of the Company at NASDAQ (PIRS) as CFO, playing a key role in transforming Pieris from a biotech Start-up to a mature biopharmaceutical company. Claus also cofounded XL-protein GmbH and led the Company to profitability through a series of collaborations with Pharma and Biotech.
Claus also supports other biotech companies in part-time management positions. He holds a Master degree in Business Administration from the University of Bamberg, Germany.
Claus Schalper
CBO
Our Partners
